ReFerm: a Postbiotic Fermented Oat Gruel Composition is Reducing Mast Cell Degranulation in the Colon of Patients with Irritable Bowel Syndrome

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2024 Jul 19

PMID 39026547

Authors

Olga Biskou

Susanna Walter

Hans Israelsen

Martin E Winberg

Olga Bednarska

Asa V Keita

Affiliations

Soon will be listed here.

Abstract

Background: Irritable bowel syndrome (IBS) is a highly prevalent gastrointestinal disorder that affects ~4% of the global population. ReFerm is a postbiotic product derived from oat gruel fermented with , and it has been shown to have beneficial effects on intestinal permeability in patients with IBS. In this study, we investigated the effects of ReFerm on regulators of intestinal permeability, namely mast cells and enteric glial cells.

Materials And Methods: A total of 30 patients with moderate to severe IBS were treated with an enema containing ReFerm or a placebo twice daily. The patients underwent sigmoidoscopy with biopsies obtained from the distal colon at baseline and after 14 days of treatment. These biopsies were processed in two ways: some were fixed, embedded in paraffin, sectioned, and stained for mast cells and enteric glial cells; others were cryopreserved, lysed, and subjected to Western blotting to analyze the same markers.

Results: Treatment with ReFerm, but not the placebo, significantly reduced mast cell tryptase protein levels in the biopsy lysates. Although the number of mast cells remained unchanged in colonic biopsies, ReFerm treatment significantly reduced mast cell degranulation, a result not observed in the placebo group. Neither ReFerm or placebo treatment had an impact on total protein levels or the number of enteric glial cells in the biopsies.

Conclusion: ReFerm treatment significantly reduced both total mast cell tryptase levels and the degranulation of mast cells in colonic biopsies from patients with IBS, suggesting a decrease in mast cell activity as a potential mechanism underlying the beneficial effects of ReFerm. However, further research is required to assess the molecular mechanisms through which ReFerm operates in the colons of patients with IBS.

Clinical Trial Registration: https://clinicaltrials.gov, identifier: NCT05475314.

References

Barnett A, Roy N, Cookson A, McNabb W . Metabolism of Caprine Milk Carbohydrates by Probiotic Bacteria and Caco-2:HT29⁻MTX Epithelial Co-Cultures and Their Impact on Intestinal Barrier Integrity. Nutrients. 2018; 10(7). PMC: 6073262. DOI: 10.3390/nu10070949. View

Folkerts J, Stadhouders R, Redegeld F, Tam S, Hendriks R, Galli S . Effect of Dietary Fiber and Metabolites on Mast Cell Activation and Mast Cell-Associated Diseases. Front Immunol. 2018; 9:1067. PMC: 5992428. DOI: 10.3389/fimmu.2018.01067. View

Bednarska O, Walter S, Casado-Bedmar M, Strom M, Salvo-Romero E, Vicario M . Vasoactive Intestinal Polypeptide and Mast Cells Regulate Increased Passage of Colonic Bacteria in Patients With Irritable Bowel Syndrome. Gastroenterology. 2017; 153(4):948-960.e3. PMC: 5623149. DOI: 10.1053/j.gastro.2017.06.051. View

Quigley E . The Gut-Brain Axis and the Microbiome: Clues to Pathophysiology and Opportunities for Novel Management Strategies in Irritable Bowel Syndrome (IBS). J Clin Med. 2018; 7(1). PMC: 5791014. DOI: 10.3390/jcm7010006. View

Vanuytsel T, Van Wanrooy S, Vanheel H, Vanormelingen C, Verschueren S, Houben E . Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism. Gut. 2013; 63(8):1293-9. DOI: 10.1136/gutjnl-2013-305690. View

He S . Key role of mast cells and their major secretory products in inflammatory bowel disease. World J Gastroenterol. 2004; 10(3):309-18. PMC: 4724914. DOI: 10.3748/wjg.v10.i3.309. View

Hosseinifard E, Morshedi M, Bavafa-Valenlia K, Saghafi-Asl M . The novel insight into anti-inflammatory and anxiolytic effects of psychobiotics in diabetic rats: possible link between gut microbiota and brain regions. Eur J Nutr. 2019; 58(8):3361-3375. DOI: 10.1007/s00394-019-01924-7. View

Klooker T, Braak B, Koopman K, Welting O, Wouters M, Van der Heide S . The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut. 2010; 59(9):1213-21. DOI: 10.1136/gut.2010.213108. View

Vanuytsel T, Bercik P, Boeckxstaens G . Understanding neuroimmune interactions in disorders of gut-brain interaction: from functional to immune-mediated disorders. Gut. 2023; 72(4):787-798. PMC: 10086308. DOI: 10.1136/gutjnl-2020-320633. View

10.

Meira de-Faria F, Casado-Bedmar M, Lindqvist C, Jones M, Walter S, Keita A . Altered interaction between enteric glial cells and mast cells in the colon of women with irritable bowel syndrome. Neurogastroenterol Motil. 2021; 33(11):e14130. DOI: 10.1111/nmo.14130. View

11.

Pochard C, Coquenlorge S, Freyssinet M, Naveilhan P, Bourreille A, Neunlist M . The multiple faces of inflammatory enteric glial cells: is Crohn's disease a gliopathy?. Am J Physiol Gastrointest Liver Physiol. 2018; 315(1):G1-G11. DOI: 10.1152/ajpgi.00016.2018. View

12.

Folkerts J, Redegeld F, Folkerts G, Blokhuis B, van den Berg M, de Bruijn M . Butyrate inhibits human mast cell activation via epigenetic regulation of FcεRI-mediated signaling. Allergy. 2020; 75(8):1966-1978. PMC: 7703657. DOI: 10.1111/all.14254. View

13.

Drossman D, Hasler W . Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology. 2016; 150(6):1257-61. DOI: 10.1053/j.gastro.2016.03.035. View

14.

Mearin F, Lacy B, Chang L, Chey W, Lembo A, Simren M . Bowel Disorders. Gastroenterology. 2016; . DOI: 10.1053/j.gastro.2016.02.031. View

15.

Vicentini F, Keenan C, Wallace L, Woods C, Cavin J, Flockton A . Intestinal microbiota shapes gut physiology and regulates enteric neurons and glia. Microbiome. 2021; 9(1):210. PMC: 8549243. DOI: 10.1186/s40168-021-01165-z. View

16.

Keita A, Alkaissi L, Holm E, Heil S, Chassaing B, Darfeuille-Michaud A . Enhanced E. coli LF82 Translocation through the Follicle-associated Epithelium in Crohn's Disease is Dependent on Long Polar Fimbriae and CEACAM6 expression, and Increases Paracellular Permeability. J Crohns Colitis. 2019; 14(2):216-229. PMC: 7008151. DOI: 10.1093/ecco-jcc/jjz144. View

17.

Ducrotte P, Sawant P, Jayanthi V . Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol. 2012; 18(30):4012-8. PMC: 3419998. DOI: 10.3748/wjg.v18.i30.4012. View

18.

Seguella L, Gulbransen B . Enteric glial biology, intercellular signalling and roles in gastrointestinal disease. Nat Rev Gastroenterol Hepatol. 2021; 18(8):571-587. PMC: 8324524. DOI: 10.1038/s41575-021-00423-7. View

19.

Bashashati M, Moossavi S, Cremon C, Barbaro M, Moraveji S, Talmon G . Colonic immune cells in irritable bowel syndrome: A systematic review and meta-analysis. Neurogastroenterol Motil. 2017; 30(1). DOI: 10.1111/nmo.13192. View

20.

Palsson O, Baggish J, Turner M, Whitehead W . IBS patients show frequent fluctuations between loose/watery and hard/lumpy stools: implications for treatment. Am J Gastroenterol. 2011; 107(2):286-95. PMC: 3855407. DOI: 10.1038/ajg.2011.358. View